Table 2.
Medication class | Number (%) of patients | Model 1 * HR (95% CI) |
Model 2 ** HR (95% CI) |
---|---|---|---|
Individual medication class | |||
Beta-blocker | 5209 (38.0%) | 0.92 (0.88, 0.95) | 0.90 (0.85,0.95) |
Statin | 4720 (35.5%) | 0.96 (0.93, 1.00) | 0.98 (0.92, 1.04) |
Insulin | 2319 (16.9%) | 0.79 (0.75, 0.82) | 0.87 (0.82, 0.92) |
Metformin | 2277 (16.6%) | 0.94 (0.89, 0.98) | 1.02 (0.93, 1.11) |
Thiazolidinedione | 1037 (7.6%) | 1.03 (0.97, 1.10) | 1.08 (1.00, 1.17) |
Warfarin | 1857 (13.6) | 0.88 (0.83, 0.92) | 0.90 (0.85, 0.95) |
Heparin | 746 (5.4%) | 0.75 (0.70, 0.81) | 0.75 (0.69, 0.82) |
Combination drug class | |||
Beta-blocker/statin | 2590 (18.9) | 0.93 (0.89, 0.98) | 1.05 (0.97, 1.15) |
Metformin/statin | 1255 (9.2%) | 0.95 (0.89, 1.01) | 1.00 (0.90, 1.11) |
Beta-blocker/metformin | 1094 (8.0%) | 0.90 (0.84, 0.96) | 0.99 (0.89, 1.10) |
HR (95% CI) - hazard ratio (95% confidence interval)
Model 1- univariate Cox regression analysis
Model 2- multivariable Cox regression analysis adjusting for age, gender, race, stage, site, and Charlson comorbidity index